Heat Biologics CEO, Jeff Wolf, to Present at the Upcoming BIO CEO & Investor Conference in New York

DURHAM, NC / ACCESSWIRE / February 7, 2018 / Heat Biologics, Inc. ("Heat") HTBX, a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, will present during the BIO CEO & Investor Conference next week in New York. Jeff Wolf, CEO of Heat, will present at 9 a.m. ET, on Tuesday, Feb. 13, 2018, and he will also be available to participate in one-on-one meetings with investors registered to attend the conference.

The BIO CEO & Investor Forum is a biotech investor conference focused on established and emerging, publicly traded and select private biotech companies. The event features plenary sessions, education sessions focused on therapeutic topics and business issues, company presentations, and one-on-one meetings.

About Heat Biologics, Inc.

Heat Biologics is a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer using of CD8+ "Killer" T-cells. Our T-Cell Activation Platform (TCAP) produces therapies designed to turn "cold" tumors "hot" and be administered in combination with checkpoint therapies and other immuno-modulators to increase their effectiveness. We are currently enrolling patients in our Phase 2 clinical trial for non-small cell lung cancer, in combination with Bristol-Myers Squibb's nivolumab (Opdivo®). We also have numerous pre-clinical programs at various stages of development. For more information, please visit www.heatbio.com.

Contact

For Media and Investor Inquiries
Melissa M Conger
Heat Biologics
+1 919 289 4017
mconger@heatbio.com

SOURCE: Heat Biologics, Inc.